Where can I find more detail on the CAPTAIN study?

  • Relative to other studies investigating triple therapy in asthma, CAPTAIN inclusion criteria were intentionally broadened to capture the heterogeneity of uncontrolled asthma seen in real-world clinical practice, with no requirement for a history of exacerbations
  • Results from this study suggest that adding a second long-acting bronchodilator, UMEC, to FF/VI dual therapy via a single inhaler, administered once daily, improves lung function in patients with poorly controlled asthma on ICS/LABA
Where can I find more detail on the CAPTAIN study? article graphic

Read the full article on The Lancet Respiratory Medicine

VIEW ARTICLE

Related materials

Presentation graphic

How does the CAPTAIN study support the use of triple therapy in asthma?

CAPTAIN provides robust evidence to support, and better tailor, the use of FF 100/UMEC/VI and FF…

FIND OUT MORE

Podcast graphic

How is LAMA positioned in the GINA guidelines?

The GINA 2020 strategy recommends a stepwise approach to asthma management. As part of step…

FIND OUT MORE

Infographic graphic

Which inhaled treatment for which patient in asthma?

CAPTAIN helps to identify which inhaled treatment for which patient in asthma…

FIND OUT MORE

Reference

  1. Lee L, et al. Lancet Respir Med, 2020.

Asthma Forward is a registered trade mark of the GSK group of companies.
©2022 GSK group of companies. All rights reserved.

SE-GBL-FVU-WCNT-200066 | December 2022